Literature DB >> 11900571

p53 protein overexpression in bone marrow biopsies of patients with Shwachman-Diamond syndrome has a prevalence similar to that of patients with refractory anemia.

M Tarek Elghetany1, Blanche P Alter.   

Abstract

CONTEXT: Shwachman-Diamond syndrome (SDS) is a rare inherited disorder characterized by pancreatic insufficiency, neutropenia, and in some patients, metaphyseal dysostosis. Patients with SDS are at a high risk for development of bone marrow failure, myelodysplastic syndrome, and acute leukemia. The p53 gene plays a major role in cell-cycle regulation, particularly in the presence of a genetic alteration in DNA, a critical step for the initiation of leukemogenesis. p53 gene up-regulation and p53 protein overexpression may occur as a cellular reaction to significant DNA damage. Shwachman-Diamond syndrome and refractory anemia patients have close similarities in the prevalence of acute leukemia and in cell-cycle changes in bone marrow cells. This similarity was further investigated for p53 protein overexpression using archived tissue from patients with hematologic diseases having various leukemic propensities, including SDS and refractory anemia.
METHODS: Immunohistochemical staining for p53 protein overexpression was performed on bone marrow biopsies from 9 patients with SDS. These specimens were compared with biopsies from 71 patients with acquired hematologic disorders with variable risk levels for leukemia, including acquired aplastic anemia (n = 14), refractory anemia (n = 46), and various acquired cytopenias (n = 11), as well as 37 control subjects.
RESULTS: p53 protein overexpression was identified only in patients with SDS and in patients with refractory anemia; these groups exhibited comparable prevalences of 78% and 72%, respectively. None of the patients with acquired aplastic anemia, acquired cytopenias, or in the control group showed overexpression of p53 protein.
CONCLUSION: The prevalence of p53 protein overexpression in SDS is significantly different from that in acquired aplastic anemia and acquired cytopenias, but it is similar to the prevalence in refractory anemia. We speculate that p53 protein overexpression in this bone marrow failure syndrome may represent an early indicator of significant DNA genetic alteration, which is a crucial step in the process of leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11900571     DOI: 10.5858/2002-126-0452-PPOIBM

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  22 in total

1.  p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

Authors:  Leonie Saft; Mohsen Karimi; Mehran Ghaderi; András Matolcsy; Ghulam J Mufti; Austin Kulasekararaj; Gudrun Göhring; Aristoteles Giagounidis; Dominik Selleslag; Petra Muus; Guillermo Sanz; Moshe Mittelman; David Bowen; Anna Porwit; Tommy Fu; Jay Backstrom; Pierre Fenaux; Kyle J MacBeth; Eva Hellström-Lindberg
Journal:  Haematologica       Date:  2014-03-28       Impact factor: 9.941

2.  Cytokine production by bone marrow mononuclear cells in inherited bone marrow failure syndromes.

Authors:  Ken Matsui; Neelam Giri; Blanche P Alter; Ligia A Pinto
Journal:  Br J Haematol       Date:  2013-07-25       Impact factor: 6.998

3.  Deficiency of the ribosome biogenesis gene Sbds in hematopoietic stem and progenitor cells causes neutropenia in mice by attenuating lineage progression in myelocytes.

Authors:  Noemi A Zambetti; Eric M J Bindels; Paulina M H Van Strien; Marijke G Valkhof; Maria N Adisty; Remco M Hoogenboezem; Mathijs A Sanders; Johanna M Rommens; Ivo P Touw; Marc H G P Raaijmakers
Journal:  Haematologica       Date:  2015-07-16       Impact factor: 9.941

Review 4.  Mechanisms of leukemic transformation in congenital neutropenia.

Authors:  Daniel C Link
Journal:  Curr Opin Hematol       Date:  2019-01       Impact factor: 3.284

5.  Somatic mutations and clonal hematopoiesis in congenital neutropenia.

Authors:  Jun Xia; Christopher A Miller; Jack Baty; Amrita Ramesh; Matthew R M Jotte; Robert S Fulton; Tiphanie P Vogel; Megan A Cooper; Kelly J Walkovich; Vahagn Makaryan; Audrey A Bolyard; Mary C Dinauer; David B Wilson; Adrianna Vlachos; Kasiani C Myers; Robert J Rothbaum; Alison A Bertuch; David C Dale; Akiko Shimamura; Laurence A Boxer; Daniel C Link
Journal:  Blood       Date:  2017-11-01       Impact factor: 22.113

6.  Shwachman-Bodian Diamond syndrome is a multi-functional protein implicated in cellular stress responses.

Authors:  Heather L Ball; Bing Zhang; J Jacob Riches; Rikesh Gandhi; Jing Li; Johanna M Rommens; Jeremy S Myers
Journal:  Hum Mol Genet       Date:  2009-07-14       Impact factor: 6.150

Review 7.  Shwachman-Diamond syndrome: a review of the clinical presentation, molecular pathogenesis, diagnosis, and treatment.

Authors:  Lauri Burroughs; Ann Woolfrey; Akiko Shimamura
Journal:  Hematol Oncol Clin North Am       Date:  2009-04       Impact factor: 3.722

8.  Bone marrow cell cycle markers in inherited bone marrow failure syndromes.

Authors:  Mohamad M Al-Rahawan; Blanche P Alter; Barbara J Bryant; M Tarek Elghetany
Journal:  Leuk Res       Date:  2008-07-07       Impact factor: 3.156

9.  Impaired ribosomal subunit association in Shwachman-Diamond syndrome.

Authors:  Nicholas Burwick; Scott A Coats; Tomoka Nakamura; Akiko Shimamura
Journal:  Blood       Date:  2012-10-31       Impact factor: 22.113

Review 10.  Significance of Clonal Mutations in Bone Marrow Failure and Inherited Myelodysplastic Syndrome/Acute Myeloid Leukemia Predisposition Syndromes.

Authors:  Eva J Schaefer; R Coleman Lindsley
Journal:  Hematol Oncol Clin North Am       Date:  2018-05-01       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.